Endeavor

Immunotherapy May Help Prevent Acute Myeloid Leukemia Relapse After Transplant

Early phase 1 trial results indicate safety and efficacy of donor gamma delta T cell infusions

Access to Treatment is Hurdle to be Conquered for Multiple Myeloma Patients

CAR T treatments have revolutionized care, but some communities struggle to receive it

Top Moffitt Research Stories of 2024

From FDA approvals to drug discovery, Moffitt led the way this past year

Personalized Vaccine Shows Promise in Early HER2-Positive Breast Cancer

Dendritic cell vaccine uses immune cells collected from the patient, which are enhanced in the lab and injected directly into the primary breast tumor

Drug Aims To Improve Transplant Success for Myelofibrosis Patients

Study shows giving patients fedratinib is safe and could help reduce chance of relapse

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms

Get to Know Moffitt Physician in Chief Dr. Karen Lu

Karen Lu, MD, is a nationally recognized physician-scientist who focuses her clinical and research interests on the surgical and medical treatment of women with ovarian and endometrial cancers

Newly Approved CAR T-Cell Therapy Gives Acute Lymphoblastic Leukemia a New Personalized Option

Novel design and tumor-guided dosing may reduce side effects while maintaining encouraging efficacy